BioSpace News Archive

TheraCell Inc., a leading allograft solution company, today announced that as of September 30, 2020 its royalty income from the licensees of its base demineralized bone fiber technology had surpassed a $1.0M annual run rate.

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that its CE-marked VITROS® SARS-CoV-2 antigen test can now detect SARS-CoV-2 infection in asymptomatic individuals.

The medical devices cuff is a replacement cuff that can be used in combination with a blood pressure monitor that is not invasive. It jointly assess blood pressure and pulse rhythm. An incorporated antimicrobial is utilized in this special cuff.

Porphyria is a group of disorders in which the substance called porphyrin accumulates in the body and affects the nervous system or skin and may cause abdominal pain. Porphyrin is an essential substance for the function of hemoglobin.

Ultrasound probe disinfection mainly is a type of high level disinfection, wherein a complete elimination of microorganisms in an environment or on an instrument is carried out.

Laboratory shakers are extensively used in microbiology and range of life sciences processes.

Precise treatment leads to resolution of patient’s debilitating symptoms and complete remodeling of her lymphatic system

Nov. 20, 2020 07:00 UTC Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS ® (ravulizumab) with Significantly Reduced Infusion Time – The new 100 mg/mL formulation will reduce infusion time by approximately 60%, lessening the burden on patients – – ULTOMIRIS is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) – BOSTON--( BUSINESS WIRE )-- Alexion Pha

CARsgen Therapeutics announced that data from its global multiple myeloma program will be presented, including two oral presentations and one poster session, at the 62nd American Society of Hematology Annual Meeting and Exposition, taking place virtually December 5-8, 2020.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, which will potentially enable use of the vaccine in high-risk populations in the U.S. by the middle to end of December 2020